Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Dow
Medtronic
McKinsey
AstraZeneca

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,801,767

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,801,767
Title:Drug eluting stent and a guide catheter device assembly for implanting the same
Abstract: The present invention relates to a drug eluting stent for delivering therapeutic agents to a body lumen. The stent includes an expandable substrate configured for implantation in a vessel of a human body and a therapeutic agent composition coated over the stent. The balloon catheter shaft has a resilient unit that helps to transmit a force to the distal end, thereby helping to cross lesions.
Inventor(s): Roy; Vipul Narain (New Delhi, IN)
Assignee:
Application Number:13/108,254
Patent Claims:1. A guide catheter device for angioplasty, comprising: a guide catheter having a proximal end, a distal end, and lumen extending therethrough; a balloon catheter placed inside the guide catheter, the balloon catheter having a proximal end, a distal end, a guide wire lumen and a balloon lumen; a fluid inflatable balloon connected to the distal end of the balloon lumen; a guide wire extending through the guide wire lumen of the balloon catheter; and a drug eluting stent mounted over the balloon in order to place the same at a desired location in the artery; wherein, the balloon catheter comprises at least one resilient unit provided at a predetermined distance from the proximal end of the balloon catheter, and is configured to absorb and transmit a required force to maintain the alignment of the guide catheter and the balloon catheter, the at least one resilient unit comprises a spring in a circular shape, spiral shape, helical shape, or a combination thereof; and edges of the stent have a higher concentration of drugs as compared to a middle segment of the stent.

2. The guide catheter device according to claim 1, wherein the stiffness of the spring is in the range of 100 N/m to 5000 N/m.

3. The guide catheter device according to claim 1, wherein the spring is provided in the range of 5-25 cm from the proximal end of the balloon.

4. The guide catheter device according to claim 1, wherein the balloon has a heat expansible material and an extended nose cone.

5. The guide catheter device according to claim 1, wherein the stent comprises a zigzag pattern stent with a cocktail of drug coatings.

6. The guide catheter device according to claim 1, wherein the spring comprises non-ferromagnetic material.

7. The guide catheter device according to claim 1, wherein the resilient unit comprises a spring ranging from 0.5 cm to 20 cm.

8. The guide catheter device according to claim 1, wherein the edges of the stent struts comprise a smoothened outer surface.

9. The guide catheter device according to claim 1, wherein strut length of the stent ranges from 1 mm to 4 mm.

10. The guide catheter device according to claim 1, wherein the stent is coated with a composition of drugs comprises: a) anticoagulants, b) a Platelet Glycoprotein IIb/IIIa Receptor blocker or antagonist, and c) a cytostasis or cytotoxic agent, wherein, the proportion of the anticoagulants, platelet glycoprotein IIb/IIIa receptor blocker or antagonist, and the cytostatis or cytotoxic agent is in the range of 1:0.15:0.5 to 1:0.2:1.

11. The guide catheter device according to claim 10, wherein the anticoagulants are selected from the qroup consisting of heparin (unfractionated/fractionated), Xa inhibitors such as Fondaparinux, ldrabiotaparinux, Otamixaban, AVE5026, low molecular weight heparin such as enoxaparin, dalteparin, nadroparin, reviparin, ardeparin, certoparin, parnaparin, tinzaparin, and direct thrombin inhibitors such as lepirudin, arqatroban, and bivalirudin, or a combination thereof.

12. The guide catheter device according to claim 10, wherein the receptor blocker is selected from the group consisting of Glycoprotein IIb/IIIa inhibitors, platelet glycoprotein IIb/IIIa inhibitors, Platelet Glycoprotein IIb/IIIa Receptor Antagonists, or Glycoprotein IIb/IIIa Antagonists), and the receptor blocker comprises abciximab, tirofiban, eptifibatide, or a combination thereof.

13. The guide catheter device according to claim 10, wherein the cytostasis or cytotoxic agent is selected from the group consisting of sirolimus, zotarolimus, tacrolimus, evrolimus, biolimus, merilimus, paclitaxel, or a combination thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
McKesson
Harvard Business School
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.